

***Fiscal Year 2020 Department of Defense Peer Reviewed Medical Research Program (PRMRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
<p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-PRMRP-CTA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> • Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the Topic Area(s) of interest. • Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials. • Investigational New Drug (IND) or Investigational Device Exemption (IDE) applications to the Food and Drug Administration (FDA), if needed, must be approved by the FDA before the PRMRP application submission deadline unless applying to the Planning Phase with Clinical Trial application category. • <i>New for FY20:</i> Optional Planning Phase available. The Planning Phase will provide support to prepare and submit an IND/IDE application to the FDA; FDA/regulatory approval to proceed is required prior to exercising option for clinical trial. 	<p><i>Planning Phase (optional):</i></p> <p>Maximum of \$500,000 for direct costs (plus indirect costs)</p> <p>Maximum period of performance is 18 months</p> <p><i>Clinical Trial:</i></p> <p>No maximum funding limit; requested funding must be appropriate for the scope of work proposed</p> <p>Maximum period of performance is 4 years</p>	<p>Pre-Application (Letter of Intent): July 29, 2020 5:00 p.m. Eastern time (ET)</p> <p>Application: August 13, 2020 11:59 p.m. ET</p>
<p>Discovery Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-PRMRP-DA</p>	<p>Postdoctoral fellow or clinical fellow (or equivalent) and above</p>	<ul style="list-style-type: none"> • Supports the exploration of a highly innovative new concept or untested theory in the Topic Area(s) of interest. • Not intended to support the logical progression of an already established line of questioning. • Clinical trials will not be funded. • Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). 	<p>Maximum funding of \$200,000 for direct costs (plus indirect costs)</p> <p>Maximum period of performance is 2 years</p>	<p>Pre-Application (Letter of Intent): May 7, 2020 5:00 p.m. Eastern time (ET)</p> <p>Application: May 21, 2020 11:59 p.m. ET</p>

***Fiscal Year 2020 Department of Defense Peer Reviewed Medical Research Program (PRMRP)
Reference Table of Award Mechanisms and Submission Requirements***

<p>Focused Program Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-PRMRP-FPA</p>	<p>Lead PI: Full Professor level or above (or equivalent)</p> <p>Project Leads: Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> • Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal in the Topic Area(s) of interest. • Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications. • Projects may range from exploratory/hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question. • Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects. • <i>Preproposal submission is required; application submission is by invitation only.</i> 	<p>Maximum funding of \$7.2 million for direct costs (plus indirect costs)</p> <p>Maximum period of performance is 4 years</p>	<p>Pre-Application (Preproposal): April 30, 2020 5:00 p.m. ET</p> <p>Application: August 13, 2020 11:59 p.m. ET</p>
<p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-PRMRP-IIRA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> • Supports research that will make an original and important contribution to the field of research and/or patient care in the Topic Area(s) of interest. • Partnering PI Option available. • Clinical trials will not be funded. • <i>Preproposal submission is required; application submission is by invitation only.</i> 	<p>Maximum funding of \$1.6 million for direct costs (plus indirect costs); \$2.0 million for direct costs (plus indirect costs) for applications including a Partnering PI Option</p> <p>Maximum period of performance is 4 years</p>	<p>Pre-Application (Preproposal): May 1, 2020 5:00 p.m. ET</p> <p>Application: September 3, 2020 11:59 p.m. ET</p>
<p>Technology/Therapeutic Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-PRMRP-TTDA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> • Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life in the Topic Area(s) of interest. • Product-oriented (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item, such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. • Clinical trials will not be funded. • <i>Preproposal submission is required; application submission is by invitation only.</i> 	<p>Maximum funding of \$4.0 million for direct costs (plus indirect costs)</p> <p>Maximum period of performance is 4 years</p>	<p>Pre-Application (Preproposal): May 1, 2020 5:00 p.m. ET</p> <p>Application: September 3, 2020 11:59 p.m. ET</p>

***Fiscal Year 2020 Department of Defense Peer Reviewed Medical Research Program (PRMRP)
Reference Table of Award Mechanisms and Submission Requirements***

<p>Clinical Trial Award (for Emerging Viral Diseases and Respiratory Health)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-PRMRP-CTA-COV</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> • Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the Topic Areas of Emerging Viral Diseases and/or Respiratory Health. • Applications must address at least one of the Focus Areas published in the Program Announcement. • Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials. • IND or IDE applications to the FDA, if needed, should be submitted to the FDA before the PRMRP application submission deadline. 	<p>Funding limit for clinical trial not defined; requested funding must be appropriate for the scope of work proposed</p> <p>Maximum period of performance is 4 years</p>	<p>Pre-Application (Letter of Intent): June 8, 2020 5:00 p.m. ET</p> <p>Application: June 22, 2020 11:59 p.m. ET</p>
<p>Investigator-Initiated Research Award (for Emerging Viral Diseases and Respiratory Health)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-PRMRP-IIRA-COV</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> • Supports research that will make an original and important contribution to the field of research and/or patient care in the Topic Areas of Emerging Viral Diseases and/or Respiratory Health. • Applications must address at least one of the Focus Areas published in the Program Announcement. • Partnering PI Option available. • Clinical trials will not be funded. 	<p>Maximum funding of \$1.6 million for direct costs (plus indirect costs); \$2.0 million for direct costs (plus indirect costs) for applications including a Partnering PI Option</p> <p>Maximum period of performance is 4 years</p>	<p>Pre-Application (Letter of Intent) May 28, 2020 5:00 p.m. ET</p> <p>Application: June 12, 2020 11:59 p.m. ET</p>
<p>Technology/Therapeutic Development Award (for Emerging Viral Diseases and Respiratory Health)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-20-PRMRP-TTDA-COV</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> • Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life in the Topic Areas of Emerging Viral Diseases and/or Respiratory Health. • Applications must address at least one of the Focus Areas published in the Program Announcement. • Product-oriented (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item, such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. • Clinical trials will not be funded. 	<p>Maximum funding of \$4.0 million for direct costs (plus indirect costs)</p> <p>Maximum period of performance is 4 years</p>	<p>Pre-Application (Letter of Intent): May 28, 2020 5:00 p.m. ET</p> <p>Application: June 12, 2020 11:59 p.m. ET</p>